Libera

What Libera does

Libera is a preclinical-stage biotechnology company developing engineered extracellular vesicles (EVs) as a delivery platform for biological therapies targeting chronic inflammatory diseases. The company's core technology enables customization of EVs to carry anti-inflammatory molecules — proteins, RNAs, and lipids — that can be directed at specific organs and cell types, with the stated dual advantage of reducing off-target effects on healthy tissue and inhibiting multiple inflammatory pathways simultaneously. Libera's therapeutic focus spans oncology, cardiovascular disease, liver inflammatory disease, neurodegenerative disease, and aging-related systemic inflammation, positioning inflammation modulation rather than any single indication as its central thesis.

The company operates from São Paulo, Brazil, with its scientific leadership and research base concentrated in Argentina, drawing on affiliations with CONICET, Universidad Austral, Universidad Nacional de Cuyo, and the Institute of Histology and Embryology of Mendoza. Its founding team combines academic researchers in EV biology, glycobiology, immunology, and oncology with a CEO (Matías Vidal) whose background is in investment banking and venture-building through Securitas Biosciences Group and Finvest Group, and a CFO (Augusto Carvalho) developing a regional healthcare thesis covering Brazil.

Libera has no commercial products, no clinical-stage assets, and no disclosed revenue. Its go-to-market model assumes eventual monetization through pharmaceutical licensing, co-development agreements, or acquisition, leveraging scientific collaborations, academic technology transfer offices, and connections to large pharmaceutical companies — including AstraZeneca, where the COO serves as a Medical Science Liaison — to build a pipeline of therapeutic candidates. The company is not yet generating product or licensing revenue and remains in the early discovery and preclinical research phase.

Name

Libera

Legal name

Libera

Website

https://liberathx.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Libera is a preclinical-stage biotech developing engineered extracellular vesicles that deliver anti-inflammatory cargoes to treat chronic inflammatory diseases spanning oncology, cardiovascular, liver, neurodegenerative, and aging indications. The company is based in São Paulo, Brazil, with research leadership rooted in Argentine academic institutions, and has no commercial products or revenue.

Ownership category

akta.pro rank

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Therapeutic Development and Licensing: As a preclinical-stage biotech company, Libera is in the early phases of drug development. Revenue generation would come from licensing deals, partnerships, or acquisitions with pharmaceutical companies once therapeutic candidates reach clinical stages. The company is not yet generating product revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Libera is a preclinical biotechnology company developing a proprietary engineered extracellular vesicle (EV) platform that designs customized vesicles carrying anti-inflammatory molecules (proteins, RNAs, lipids) to target specific organs and cell types. The platform is intended to treat chronic inflammatory diseases including cancer, cardiovascular, liver inflammatory, neurodegenerative, and aging-related conditions. No products are commercialized; the company is positioned for future licensing or co-development deals with pharmaceutical partners.

Product overview

Libera is a biotechnology company developing a single unified platform based on engineered extracellular vesicles (EVs) for treating chronic inflammatory diseases. The platform enables the design of customized EVs carrying anti-inflammatory molecules (proteins, RNAs, lipids) that target specific organs and cell types. The company's therapeutic focus spans cancer, cardiovascular diseases, liver inflammatory diseases, neurodegenerative diseases, and aging-related conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Engineered Extracellular Vesicle (EV) Platform

Quantifiable outcome

• Platform enables simultaneous inhibition of multiple inflammatory molecules and pathways, increasing therapeutic success probability

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• CONICETcoreStrategic or Co-development PartnerNational Scientific and Technical Research Council (Argentina). Multiple team members (CSO Matias Ostrowski, Head of EVs Engineering Diego Croci, Manager Victoria Sundblad) hold research positions at CONICET. Provides research infrastructure and scientific expertise in extracellular vesicle biology and immunology.
• Universidad AustralcoreStrategic or Co-development PartnerMultiple team members are affiliated with Universidad Austral including CMO Norberto J. Maggini (Director of Technology Transfer Office), Nicolás Kitashima (Operations Director of Institute of Applied AI), and Ventura Simonovich (Clinical Operations Consultant). The university provides clinical research capabilities and technology transfer infrastructure.
• AstraZenecaminorStrategic or Co-development PartnerCOO Co-founder Juan Pablo Cerliani currently serves as Medical Science Liaison in the Oncology department at AstraZeneca, creating a connection to a major pharmaceutical company.
• IHEM-MendozaminorStrategic or Co-development PartnerInstitute of Histology and Embryology of Mendoza. Diego Croci serves as Head of Laboratory of Glycobiology and Vascular Biology at IHEM-Mendoza.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Rion (Rion Inc.): Japan-based biotech developing exosome-based therapeutics (Pure-EXO platform) for wound healing, inflammatory, and regenerative indications. Comparable engineered-EV therapeutic developer with clinical assets.
• Evox Therapeutics: UK-based clinical-stage biotech engineering exosomes/EVs to deliver protein, RNA, and small-molecule therapeutics, including for inflammatory and rare diseases. Most directly comparable peer to Libera's engineered-EV platform approach.
• ILIAS Biologics: Korean biotech developing engineered exosomes (EXO-PACE platform) loaded with therapeutic proteins for inflammatory and rare diseases. Directly comparable as an engineered-EV therapeutic developer at similar preclinical-to-early-clinical stage.
• Capricor Therapeutics: US clinical-stage biotech developing extracellular vesicle-based therapeutics (CAP-1002, derived from cardiosphere-derived cells) for cardiac and inflammatory indications. Closely comparable EV therapeutic modality and indication overlap in cardiovascular inflammation.
• Arcturus Therapeutics: Clinical-stage RNA medicines company using lipid nanoparticle and exosome-based delivery systems (LUNAR platform) for infectious disease, rare disease, and inflammatory indications. Comparable in lipid/delivery-vehicle approach and inflammation pipeline.

Broad incumbents

• AbbVie: Global pharma leader in immunology/inflammation (Humira, Skyrizi, Rinvoq). Serves as the dominant incumbent buyer of inflammation assets and a likely licensing or acquisition counterparty for Libera's eventual clinical assets.
• Amgen: Major inflammation biologics franchise (Enbrel, Otezla, Tezspire) with active external innovation in next-generation anti-inflammatory modalities including cell-derived and EV-based approaches.
• Pfizer: Large inflammation and immunology pipeline (Cibinqo, Litfulo, etrasimod) actively sourcing novel inflammation modalities through BD; representative big-pharma acquirer/partner benchmark for valuation.
• Codiak BioSciences: Was a leading clinical-stage engineered exosome platform (engEx) developer for inflammatory and oncology indications before winding down operations in 2023 after clinical setbacks. Highly relevant reference for the engineered-EV therapeutic model and its failure modes.

Regional players

• mAbxience: Argentina-based biotech manufacturer of biosimilars and biologics, part of the local life-sciences ecosystem. Relevant regional benchmark for Argentine biotech scale and a potential local manufacturing/licensing counterpart.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/liberathx

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Libera